Answers are grounded in this paper and cite their sources.
To the Editor: Hannon et al.(1) recently reported a comparison of the performances of a panel of biochemical markers of bone turnover in terms of intraindividual variability (CVi) and response to hormone replacement therapy (HRT). CVi was assessed from four samples collected over 6 months in 11 women without any treatment (mean age 54 years) and response to HRT was investigated in 11 women of similar age treated by transdermal estradiol for 6 months. The reported CVi were similar for the different serum bone formation markers, but large differences were observed for the urinary resorption markers. Surprisingly, CVi was much higher for urinary cross‐linked C‐telopeptides (CTx) than for cross‐linked N‐telopeptides (NTx) (47.7% vs. 24.3%). Thus, despite the fact that urinary CTx demonstrated the largest decrease after 6 months of HRT, the number of individuals identified as responders, i.e., patients characterized by a decrease of bone marker level greater than the least significant change (LSC) cut‐off, which is based on CVi in controls was the lowest level (2 out of 10). As Hannon et al.,(1) we believe that the issue of intraindividual variability of biochemical measurements is of crucial importance to judge the utility of bone markers in monitoring treatment efficacy in a single patient. Following are our results, which differ markedly from those of Hannon et al.(1)
No takes yet. Share an insight, caveat, or question.
Garnero et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: